Myriad International GmbH develops modern diagnostics that not only make treatment decisions easier, but also take into account high scientific standards and the practical requirements of practicality in everyday clinical practice.

Myriad International provides the EndoPredict Test here, one KIT-based gene expression test to precisely determine the probability of distant metastasis 10 years after diagnosis of primary breast cancer using only anti-hormonal treatment, i.e. without chemotherapy.

This test was developed by Sividon Diagnostics GmbH, a leading company in breast cancer prognosis, which was founded in 2010 as a “management buy-out” by Siemens Healthcare Diagnostics. Sividon Diagnostics was published on May 31, 2016 by Myriad Genetics acquired and renamed Myriad International GmbH in February 2018.